Cantabio Pharmaceuticals, Inc.

Equities

CTBO

US13808X2036

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:08:59 2021-08-19 pm EDT			5-day change	1st Jan Change
1.01 ^USD	-95.96%		-.--%	-.--%

2019	Cantabio Pharmaceuticals and Luxembourg Institute of Health Collaborate Researches the Therapeutic targeting of the DJ 1 Protein to Treat Immune Associated Diseases	CI
2019	Cantabio Pharmaceuticals Inc. will Change its Ticker to CTBO from CTBOD	CI

Cantabio Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018

June 17, 2019 at 02:19 pm EDT

Cantabio Pharmaceuticals Inc. announced earnings results for the third quarter ended December 31, 2018. For the third quarter, the company announced operating loss was USD 240,192 compared to USD 166,029 a year ago. Net income was USD 342,967 compared to net loss of USD 463,483 a year ago. Basic eps was USD 0 compared to basic loss per share of USD 0.02 a year ago. For the nine months, operating loss was USD 710,195 compared to USD 730,294 a year ago. Net loss was USD 692,512 compared to USD 1.161 million a year ago. Basic loss per share was USD 0.01 compared to USD 0.04 a year ago.

Latest news about Cantabio Pharmaceuticals, Inc.

Cantabio Pharmaceuticals and Luxembourg Institute of Health Collaborate Researches the Therapeutic targeting of the DJ 1 Protein to Treat Immune Associated Diseases	19-10-21	CI
Cantabio Pharmaceuticals Inc. will Change its Ticker to CTBO from CTBOD	19-07-17	CI
Cantabio Pharmaceuticals Inc. will Change its Ticker to CTBO.D from CTBO	19-06-20	CI
Cantabio Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	19-06-17	CI
Cantabio Pharmaceuticals Inc. Announces Expiration of Employment Agreement with Simon Peace as Chief Financial Officer	19-03-21	CI
Cantabio Pharmaceuticals Inc. Announces Resignation of Simon Peace from the Board	18-12-14	CI
Cantabio Pharmaceuticals Inc. Appoints Max Zhu as a Director	18-10-15	CI
Cantabio Pharmaceuticals, Inc. announced that it has received $0.3 million in funding from Yorkville Advisors Global LP	18-06-04	CI
Cantabio Pharmaceuticals Inc. to Present Positive in Vivo Efficacy Data in A Mice Model of Parkinson’S Disease from Its Dj-1 Protein Targeting Therapeutic Program At the Neuro4d Conference in Mainz, Germany	18-05-09	CI
Cantabio Pharmaceuticals, Inc. announced that it has received $0.3 million in funding from Yorkville Advisors Global LP	18-02-13	CI
Cantabio Pharmaceuticals, Inc. announced that it expects to receive $0.3 million in funding from Yorkville Advisors Global LP	17-11-19	CI
Cantabio Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Yorkville Advisors Global LP	17-05-02	CI
Cantabio Pharmaceuticals Inc. to Present Results from Its Tau Protein Targeting Therapeutic Program for the Treatment of Alzheimer's Disease At the 13th International Conference on Alzheimer's and Parkinson's Disease	17-02-14	CI
Cantabio Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Yorkville Advisors Global LP	17-01-24	CI
Cantabio Pharmaceuticals Inc. Enters into a Licensing Agreement with Cambridge Enterprise Limited	16-09-06	CI
Cantabio Pharmaceuticals, Inc. to Present Results from its DJ-1 Protein Targeting Therapeutic Programs	16-08-18	CI
Cantabio Pharmaceuticals, Inc. and Purdue Research Foundation Sign Cooperation Agreement to Investigate the Targeting of DJ-1 Protein	16-07-11	CI
Cantabio Pharmaceuticals Inc. Announces the Development of Small Molecule Chaperones of the Abeta Peptide for the Treatment of Alzheimer's Disease in Collaboration with Novalix	16-04-12	CI
Gardedam Therapeutics, Inc. acquired Cantabio Pharmaceuticals Inc. in a reverse merger transaction.	15-12-17	CI
Cantabio Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	15-12-17	CI

Chart Cantabio Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company. The Company is focused on commercializing therapies and the intellectual property generated from its research and development activities for Parkinsonâs disease (PD), Alzheimerâs disease (AD) and other related neurodegenerative diseases. The Companyâs small molecule therapy candidates program (CB101) and protein therapy candidate (CB201) targets Parkinsonâs disease and a range of neurodegenerative diseases including Alzheimerâs disease, amyotrophic lateral sclerosis (ALS), Huntingtonâs disease and stroke. It also has two additional small molecule pharmacological chaperone programs for the treatment of Alzheimerâs Disease (and other related dementias); CB301, targeting the Tau protein, for the development of Alzheimerâs therapeutics, and CB401, targeting the AÃ peptide in Alzheimerâs drug research. The Companyâs strategy integrates therapeutic focus on targeting family biophysics and drug discovery technology.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CANTABIO PHARMACEUTICALS, INC.	-.--%	24.35K
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+47.41%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research